Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment

Pediatric Dermatology

Volumn 24, Issue 2, 2007, Pages 172-176

  Connelly, Elizabeth Alvarez ^a   Aber, Cheryl ^a   Kleiner, Gary ^a   Nousari, Carlos ^a   Charles, Carlos ^a   Schachner, Lawrence A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; DESMOGLEIN 1; DIPHENHYDRAMINE; IMMUNOGLOBULIN; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; PSEUDOMONIC ACID; RITUXIMAB; VANCOMYCIN; XIPAMIDE;

ANASARCA; ARTICLE; ATOPIC DERMATITIS; BACTEREMIA; BODY SURFACE; CASE REPORT; COMMUNITY HOSPITAL; DISEASE ACTIVITY; DISEASE COURSE; DRUG WITHDRAWAL; EPIDERMOLYSIS BULLOSA; EROSION; ERYTHRODERMA; FEMALE; FEVER; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; ICHTHYOSIS; IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE; KERATINOCYTE; LYMPHOCYTIC INFILTRATION; NUTRITIONAL DEFICIENCY; PEMPHIGUS FOLIACEUS; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEROLOGY; SKIN ABSCESS; SKIN BIOPSY; SKIN EXFOLIATION; TACHYCARDIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; DERMATITIS, EXFOLIATIVE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT; PEMPHIGUS;

EID: 33947623611     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2007.00369.x     Document Type: Article

References (27)

1. Bystryn J-C, Rudolph JL. Pemphigus. Lancet 2005;366:61-73.
2. Hashimoto T. Recent advances in the study of the pathophysiology of pemphigus. Arch Dermatol Res 2003;295:s2-s11.
3. Diaz LA, Sampaio SA, Rivitti EA et al. Endemic pemphigus foliaceus (fogo selvagem). I. Clinical features and immunopathology. J Am Acad Dermatol 1989;20:657-669.
4. Metry DW, Herbert AA, Jordon RE. Nonendemic pemphigus foliaceus in children. J Am Acad Dermatol 2002;46:419-422.
5. Ribeiro AMQ, Alvarez RRA, Friedman H et al. The profile of fogo selvagem (endemic pemphigus foliaceus) at the University Hospital of Brasilia-Brazil. Epidemiological and clinical considerations. Int J Dermatol 2005;44:293-298.
6. Grillo-Lopez AJ. Rituximab: an insider's historical perspective. Semin Oncol 2000;27(Suppl. 12):9-16.
7. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer 2001;85:1619-1623.
8. Patel DD. B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum 2002;46:1984-1985.
9. Looney RJ. Treating human autoimmune diseases by depleting B cells. Ann Rheum Dis 2002;61:863-866.
10. Quartier P, Brethon B, Phillippet P et al. Treatment of childhood autoimmune hemolytic anemia with rituximab. Lancet 2001;358:1511-1513.
11. Anolik JH, Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 2005;19:859-878.
12. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17:511-512.
13. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-888.
14. Levine TD. A pilot study of rituximab therapy for refractory dermatomyositis. Arthritis Rheum 2002;46(Suppl. 9):S488.
15. Arin MJ, Engert A, Krieg T et al. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005;153:620-625.
16. Goebeler M, Herzog S, Brocker EB et al. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003;149:899-901.
17. Dupuy A, Viguier M, Bedane C et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004;140:91-96.
18. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004;51:817-819.
19. Arin MJ, Hunzelmann N. Anti-B cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus - an update. Eur J Dermatol 2005;15:224-230.
20. Chira P, Sandborg CI. Novel therapies in pediatric rheumatic diseases. Curr Opin Pediatr 2003;15:579-585.
21. Schmidt E, Herzog S, Brocker EB et al. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005;153:449-451.
22. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders. Arthritis Rheum 2003;48:1484-1492.
23. Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother 2004;58:299-309.
24. Schmidt E, Hunzelmann N, Zillikens D et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006;31:503-508.
25. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma in combination of chimeric anti-CD 20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-276.
26. Marcus R, Imrie K, Belch A. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423.
27. Solal-Celigny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res 2006;30S1:S16-S21.